Literature DB >> 3085533

A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators.

E Angles-Cano.   

Abstract

A new spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA), specific for the quantitation of tissue plasminogen activators, is described. The method is based on (1) the high-affinity binding (Kp = 1.4 +/- 2 nM) of tPA to a solid-phase fibrin network constructed by thrombin proteolysis of fibrinogen covalently coupled to polyglutaraldehyde-activated polyvinyl chloride microtiter plates, and (2) the subsequent development of PA activity by the fibrin-tPA complex and its measurement with a coupled assay using a chromogenic substrate highly selective for plasmin. Conditions were chosen such that the rate of para-nitroaniline release from the substrate is directly proportional to the concentration of tPA. The support is able to isolate tPA from the bulk of proteins present in any biological fluid allowing the assay to specifically detect tPA activity (range: 0.01 to 50 IU/ml) even in the presence of other activators, proteases, and inhibitors. Since the assay is done in a well-defined reaction mixture (the fibrin-tPA complex, plasminogen, and the synthetic substrate), kinetics studies using pure or crude tPA can be performed. Standard curves (rate measurement and endpoint methods) were made using the international standard (preparation 83/517) for tPA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085533     DOI: 10.1016/0003-2697(86)90082-5

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

1.  Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.

Authors:  Cai-Sheng Lu; Arash A Horizon; Kwan-Ki Hwang; John FitzGerald; Wei-Shiang Lin; Bevra H Hahn; Daniel J Wallace; Allan L Metzger; Michael H Weisman; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2005-12

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

3.  Stressed neurons protect themselves by a tissue-type plasminogen activator-mediated EGFR-dependent mechanism.

Authors:  E Lemarchand; E Maubert; B Haelewyn; C Ali; M Rubio; D Vivien
Journal:  Cell Death Differ       Date:  2015-06-12       Impact factor: 15.828

4.  Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis.

Authors:  Romaric Lacroix; Laurent Plawinski; Stéphane Robert; Loïc Doeuvre; Florence Sabatier; Sara Martinez de Lizarrondo; Anna Mezzapesa; Francine Anfosso; Aurelie S Leroyer; Pascale Poullin; Noémie Jourde; Makon-Sébastien Njock; Chantal M Boulanger; Eduardo Anglés-Cano; Françoise Dignat-George
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 5.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

6.  The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.

Authors:  D Rouy; E Anglés-Cano
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

7.  39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.

Authors:  I Warshawsky; G Bu; A L Schwartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.

Authors:  C Masson; E Angles-Cano
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

9.  Kinin-generating cascade in advanced cancer patients and in vitro study.

Authors:  Y Matsumura; K Maruo; M Kimura; T Yamamoto; T Konno; H Maeda
Journal:  Jpn J Cancer Res       Date:  1991-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.